Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Obesity
Biotech
Skye's CB1 blocker fails to reduce weight in obesity study
Skye Bioscience’s obesity candidate has failed to reduce weight in a phase 2 study, marking another setback for the CB1 inhibitor class.
James Waldron
Oct 6, 2025 7:55am
Fractyl delivers data on its device for GLP-1 weight maintenance
Sep 30, 2025 12:10pm
Roche's obesity ambition not reliant on one megablockbuster
Sep 23, 2025 7:45am
Roche unveils strategy to become 'top 3' obesity company
Sep 22, 2025 8:05am
What’s next for Roche’s expensive obesity pipeline?
Sep 19, 2025 10:16am
Lilly rounds out orforglipron data ahead of obesity filings
Sep 17, 2025 9:00am
